dr. kopetz discusses triplet therapy for braf-mutant crc
Published 6 years ago • 150 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
1:44
dr. kopetz discusses the treatment of braf-mutant crc
-
1:11
dr. kopetz on the rationale for the beacon crc study in braf v600e-mutant mcrc
-
1:09
dr. kopetz on updated data from beacon crc study in braf v600e–mutant crc
-
7:02
triplet regimens in braf-mutant metastatic crc
-
6:01
beacon trial: triplet therapy in braf v600e–mutated mcrc
-
0:54
dr. kopetz on safety data from beacon crc trial in braf v600e-mutant mcrc
-
1:07
dr. eng on ongoing studies for braf-mutant crc
-
1:06
scott kopetz, md, explains how braf mutations figure into treatment algorithms for crc
-
1:51
dr. eng discusses the beacon crc study in braf-mutated crc
-
0:38
scott kopetz, md, phd, facp, discusses the incidence of braf mutation in crc patients
-
0:54
triplet therapy for certain patients with metastatic crc shows promise, but more research is needed
-
1:35
scott kopetz, md, shares updates from the beacon trial in braf-mutant colorectal cancer
-
1:39
dr. kopetz on the significance of tumor sidedness in crc
-
1:38
dr. kopetz on the correlation between tumor sidedness and biomarkers in crc
-
2:16
dr. kim on treatment for braf-mutant colon cancer
-
4:19
targeting braf in metastatic crc
-
1:34
dr. kopetz on the biology of right- versus left-sided crc
-
20:52
what is the optimal therapy for braf mutant metastatic colorectal cancer?
-
1:32
dr. flaherty on the rationale to explore triplet therapy in braf v600e-mutant melanoma